Innovative Research Award
Shuai Li
Regeneron Pharmaceuticals, Inc., United States
Shuai Li has developed a research portfolio spanning biopharmaceutical formulation development, gene therapy analytics, metabolic engineering, and synthetic biology, with research outputs published in peer-reviewed journals and presented at major scientific conferences.[1] The Innovative Research Award recognizes emerging scientific contributions demonstrating originality, interdisciplinary relevance, and measurable research impact within applied scientific and pharmaceutical innovation. His work at REGENERON and prior academic institutions has focused on analytical characterization of adeno-associated virus (AAV) systems, bioprocess optimization, and translational pharmaceutical technologies.[2]
Abstract
Shuai Li is a researcher working in pharmaceutical sciences, biotechnology, and chemical engineering with emphasis on biologics formulation, gene therapy product characterization, and metabolic engineering. His research integrates analytical chemistry, bioprocess optimization, and automation-driven pharmaceutical development methodologies. Current work at Regeneron Pharmaceuticals, Inc. focuses on accelerated stability optimization platforms, adeno-associated virus formulation technologies, and analytical workflows supporting translational biopharmaceutical development.[2] Previous academic contributions include metabolic pathway engineering in engineered Escherichia coli, dynamic metabolic control systems, and supramolecular chemistry investigations.[3]
Keywords
Biopharmaceutical formulation, AAV stability, gene therapy, metabolic engineering, synthetic biology, analytical chemistry, pharmaceutical sciences, biotechnology, automation platforms, protein engineering.
Introduction
The development of advanced therapeutic biologics and gene therapy systems has accelerated the need for robust analytical technologies, scalable manufacturing workflows, and stability-driven formulation design. Contemporary pharmaceutical research increasingly requires interdisciplinary expertise spanning biotechnology, analytical chemistry, and process engineering.[4] Within this scientific context, Shuai Li has contributed to research involving AAV analytical characterization, formulation optimization, and engineered microbial biosynthesis systems aimed at improving pharmaceutical process efficiency and therapeutic development strategies.[5]
His research activities include high-throughput formulation screening, automated analytical platforms, process transfer methodologies, and characterization techniques supporting preclinical and clinical biologic development. The integration of engineering principles with pharmaceutical sciences has positioned his work within broader efforts to improve stability, manufacturability, and translational feasibility in therapeutic product development.[2]
Research Profile
Shuai Li currently serves as Principal Scientist at Regeneron Pharmaceuticals, Inc. in the United States, where his work centers on drug substance and drug product formulation development for biologics and novel therapeutic modalities, including AAV-based systems and antibody therapeutics.[2] His responsibilities include formulation stability studies, analytical method implementation, developability assessment, and technology transfer to manufacturing environments.
Prior academic research at Duke University focused on dynamic metabolic control systems, engineered microbial biosynthesis, and protein engineering methodologies for chemical production pathways. Earlier work at the Institute of Chemistry, Chinese Academy of Sciences, explored supramolecular chirality, chiral self-assembly, and molecular recognition systems.[3]
- Principal Scientist, REGENERON Pharmaceuticals
- Ph.D. in Chemical and Biological Engineering from Duke University
- Research experience in pharmaceutical sciences and synthetic biology
- Conference session chair at ASGCT scientific meetings
- Contributor to analytical and formulation technologies for AAV therapeutics
Research Contributions
Shuai Li has contributed to the development of automated high-throughput systems for accelerated AAV stability optimization and analytical workflows supporting therapeutic characterization.[5] His work includes optimization of SEC methods for characterization of genome DNA leakage in adeno-associated virus products and analytical assessment of degradation pathways under stress conditions.[6]
In metabolic engineering research, he investigated dynamic control mechanisms to improve NADPH fluxes and xylitol biosynthesis in engineered microbial systems. These studies contributed to scalable and process-robust production approaches in engineered E. coli systems.[3]
Additional contributions include development of co-formulation methods, automation-assisted analytical workflows, and biochemical characterization methodologies relevant to pharmaceutical manufacturing and translational biotechnology.[2]
Publications
- Li, S.; Wang, X.; Zhi, L.; Shameem, M.; Liu, D. “A high-throughput automation platform for accelerated AAV stability optimization.” Pharmaceutics, 2026.
- Li, S.; Wang, X.; et al. “Development of an optimized SEC method for characterization of genome DNA leakage from adeno-associated virus products.” Analytical and Bioanalytical Chemistry, 2024.
- Li, S.; Ye, Z.; Moreb, E. A.; et al. “2-Stage microfermentations.” Metabolic Engineering Communications, 2024.
- Sun, Y.; Li, S.; et al. “Alanine-Based Chiral Metallogels via Supramolecular Coordination Complex Platforms.” Journal of the American Chemical Society, 2018.
Research Impact
Shuai Li reflect interdisciplinary integration between pharmaceutical development, analytical chemistry, and metabolic engineering. His scientific contributions have supported analytical characterization strategies for gene therapy systems, including AAV stability and degradation profiling.[5] The combination of automation-driven formulation platforms and scalable bioprocess methodologies demonstrates relevance to modern translational pharmaceutical research environments.
Bibliometric indicators associated with the profile include citations, peer-reviewed publications, conference presentations, and patent filings connected to therapeutic formulation and engineered biosynthesis technologies.[1] Participation as session chair and reviewer within scientific conferences further reflects engagement with the broader biotechnology and pharmaceutical research community.[2]
Award Suitability
Shuai Li demonstrates suitability for recognition within the Innovative Research Award category through contributions spanning biopharmaceutical formulation science, AAV characterization technologies, metabolic engineering, and analytical platform development.[4] His work combines translational applicability with interdisciplinary scientific methodologies relevant to pharmaceutical development and biotechnology innovation.
The profile further reflects active participation in scientific dissemination through peer-reviewed publications, conference leadership activities, patent filings, and collaborative research contributions. The integration of automation, analytical science, and therapeutic product development supports the broader objectives associated with applied scientific innovation awards.[2]
Conclusion
Shuai Li has established a multidisciplinary research profile integrating pharmaceutical sciences, analytical chemistry, biotechnology, and metabolic engineering. His work contributes to the development of advanced analytical methods, formulation technologies, and scalable therapeutic development systems relevant to contemporary biologics and gene therapy research. Through academic publications, patents, scientific leadership activities, and translational research efforts, the profile demonstrates alignment with the objectives of the Innovative Research Award and the Applied Scientist Awards program.[1]
External Links
References
- Elsevier. (n.d.). Scopus author details: Shuai Li, Author ID 60626088100. Scopus.
https://www.scopus.com/authid/detail.uri?authorId=60626088100
- Li, S. (2026). Professional Curriculum Vitae and Research Profile. REGENERON Pharmaceuticals.
https://scholar.google.com/citations?user=gGjwsxkAAAAJ&hl=en
- Li, S.; Ye, Z.; Moreb, E. A.; et al. (2021). Dynamic control over feedback regulatory mechanisms improves NADPH fluxes and xylitol biosynthesis in engineered E. coli. Metabolic Engineering, 64, 26-40.
https://doi.org/10.1016/j.ymben.2020.12.002
- Li Zhang, Han-Xiao Wang, Shuai Li, Minghua Liu. Supramolecular chiroptical switches.
https://pubs.rsc.org/en/content/articlehtml/2020/cs/d0cs00191k
- Li, S,. et al. HardwareX (2021). BioSamplr: An open source, low cost automated sampling system for bioreactors. Pharmaceutics, 18(5), 608.
https://www.sciencedirect.com/science/article/pii/S2468067221000067
- Chen, Y.; Li, S.; Li, S.; et al. (2023). Lyophilization as an effective tool to develop AAV8 gene therapy products for refrigerated storage
https://www.sciencedirect.com/science/article/pii/S0378517323009857